Carl Dambkowski Sells 6,665 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 6,665 shares of the business's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $46.07, for a total value of $307,056.55. Following the transaction, the insider now directly owns 260,798 shares of the company's stock, valued at $12,014,963.86. This represents a 2.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $59.12, for a total transaction of $394,034.80.
• On Wednesday, October 2nd, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $56.26, for a total value of $374,972.90.

Apogee Therapeutics Price Performance

Shares of APGE traded up $2.81 on Friday, hitting $49.97. The company's stock had a trading volume of 438,600 shares, compared to its average volume of 499,271. The company has a 50 day moving average price of $52.57 and a 200 day moving average price of $48.32. Apogee Therapeutics, Inc. has a fifty-two week low of $19.91 and a fifty-two week high of $72.29. The company has a market capitalization of $2.25 billion, a PE ratio of -20.65 and a beta of 2.30.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on APGE shares. Wedbush increased their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an "outperform" rating in a research note on Monday. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They set a "buy" rating and a $89.00 price target for the company. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating and a $89.00 price objective on the stock. Finally, Guggenheim restated a "buy" rating and set a $110.00 target price (up previously from $95.00) on shares of Apogee Therapeutics in a research report on Tuesday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $83.88.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Arizona State Retirement System increased its position in Apogee Therapeutics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company's stock valued at $236,000 after acquiring an additional 258 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Apogee Therapeutics by 21.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock valued at $94,000 after purchasing an additional 285 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Apogee Therapeutics in the 3rd quarter worth approximately $71,000. Principal Financial Group Inc. lifted its holdings in Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company's stock worth $253,000 after buying an additional 1,340 shares in the last quarter. Finally, Handelsbanken Fonder AB boosted its position in Apogee Therapeutics by 25.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company's stock valued at $517,000 after buying an additional 1,800 shares during the last quarter. 79.04% of the stock is owned by institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.